-
1
-
-
84889606709
-
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
-
Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504(7478):138–142.
-
(2013)
Nature
, vol.504
, Issue.7478
, pp. 138-142
-
-
Johannessen, C.M.1
Johnson, L.A.2
Piccioni, F.3
-
2
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
-
(2010)
N Engl J Med
, vol.363
, Issue.9
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
3
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
-
(2002)
Nature
, vol.417
, Issue.6892
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
-
4
-
-
0037228055
-
High frequency of BRAF mutations in nevi
-
Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20.
-
(2003)
Nat Genet
, vol.33
, Issue.1
, pp. 19-20
-
-
Pollock, P.M.1
Harper, U.L.2
Hansen, K.S.3
-
5
-
-
0030977312
-
Endothelial apoptosis in Braf-deficient mice
-
Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet. 1997;16(3):293–297.
-
(1997)
Nat Genet
, vol.16
, Issue.3
, pp. 293-297
-
-
Wojnowski, L.1
Zimmer, A.M.2
Beck, T.W.3
-
6
-
-
4544302751
-
Switching on kinases: Oncogenic activation of BRAF and the PDGFR family
-
Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer. 2004;4(9):718–727.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.9
, pp. 718-727
-
-
Dibb, N.J.1
Dilworth, S.M.2
Mol, C.D.3
-
8
-
-
79960027865
-
BRAF targeted therapy changes the treatment paradigm in melanoma
-
Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426–433.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, Issue.7
, pp. 426-433
-
-
Ribas, A.1
Flaherty, K.T.2
-
9
-
-
84868481873
-
Vemurafenib: The first drug approved for BRAF-mutant cancer
-
Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):73–886.
-
(2012)
Nat Rev Drug Discov
, vol.11
, Issue.11
, pp. 73-886
-
-
Bollag, G.1
Tsai, J.2
Zhang, J.3
-
10
-
-
80054044954
-
Vemurafenib in melanoma with BRAF V600E mutation
-
author reply 1450
-
Morita H, Nagai R. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448. author reply 1450.
-
(2011)
N Engl J Med
, vol.365
, Issue.15
, pp. 1448
-
-
Morita, H.1
Nagai, R.2
-
11
-
-
79959795786
-
BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
12
-
-
84863116743
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
-
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.
-
(2012)
N Engl J Med
, vol.366
, Issue.8
, pp. 707-714
-
-
Sosman, J.A.1
Kim, K.B.2
Schuchter, L.3
-
13
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
-
(2012)
Lancet
, vol.380
, Issue.9839
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
14
-
-
84861083983
-
RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers
-
Falchook G, Long G, Kurzrock R, et al. RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers. Lancet. 2012;379(9829):1893.
-
(2012)
Lancet
, vol.379
, Issue.9829
, pp. 1893
-
-
Falchook, G.1
Long, G.2
Kurzrock, R.3
-
15
-
-
84856190949
-
RAF around the edges–the paradox of BRAF inhibitors
-
Weeraratna AT. RAF around the edges–the paradox of BRAF inhibitors. N Engl J Med. 2012;366(3):271–273.
-
(2012)
N Engl J Med
, vol.366
, Issue.3
, pp. 271-273
-
-
Weeraratna, A.T.1
-
16
-
-
84864285936
-
BRAF inhibition and beyond in advanced melanoma
-
Margolin K. BRAF inhibition and beyond in advanced melanoma. Lancet. 2012;380(9839):320–322.
-
(2012)
Lancet
, vol.380
, Issue.9839
, pp. 320-322
-
-
Margolin, K.1
-
17
-
-
79951961755
-
Resistance to BRAF inhibition in melanomas
-
Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772–774.
-
(2011)
N Engl J Med
, vol.364
, Issue.8
, pp. 772-774
-
-
Solit, D.B.1
Rosen, N.2
-
18
-
-
84861091160
-
Extending the reach of BRAF-targeted cancer therapy
-
Gibney GT, Sondak VK. Extending the reach of BRAF-targeted cancer therapy. Lancet. 2012;379(9829):1858–1859.
-
(2012)
Lancet
, vol.379
, Issue.9829
, pp. 1858-1859
-
-
Gibney, G.T.1
Sondak, V.K.2
-
19
-
-
78650309875
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
-
Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–972.
-
(2010)
Nature
, vol.468
, Issue.7326
, pp. 968-972
-
-
Johannessen, C.M.1
Boehm, J.S.2
Kim, S.Y.3
-
20
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–430.
-
(2010)
Nature
, vol.464
, Issue.7287
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
Shokat, K.M.4
Rosen, N.5
-
21
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387–390.
-
(2011)
Nature
, vol.480
, Issue.7377
, pp. 387-390
-
-
Poulikakos, P.I.1
Persaud, Y.2
Janakiraman, M.3
-
22
-
-
78649436372
-
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
-
Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010;3(149):ra84.
-
(2010)
Sci Signal
, vol.3
, Issue.149
-
-
Corcoran, R.B.1
Dias-Santagata, D.2
Bergethon, K.3
Iafrate, A.J.4
Settleman, J.5
Engelman, J.A.6
-
23
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–977.
-
(2010)
Nature
, vol.468
, Issue.7326
, pp. 973-977
-
-
Nazarian, R.1
Shi, H.2
Wang, Q.3
-
24
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209–221.
-
(2010)
Cell
, vol.140
, Issue.2
, pp. 209-221
-
-
Heidorn, S.J.1
Milagre, C.2
Whittaker, S.3
-
25
-
-
0037194728
-
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
-
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418(6901):934.
-
(2002)
Nature
, vol.418
, Issue.6901
, pp. 934
-
-
Rajagopalan, H.1
Bardelli, A.2
Lengauer, C.3
Kinzler, K.W.4
Vogelstein, B.5
Velculescu, V.E.6
-
26
-
-
84856217925
-
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
-
Xing F, Persaud Y, Pratilas CA, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2012;31(4):446–457.
-
(2012)
Oncogene
, vol.31
, Issue.4
, pp. 446-457
-
-
Xing, F.1
Persaud, Y.2
Pratilas, C.A.3
-
27
-
-
77956513286
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
-
Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–599.
-
(2010)
Nature
, vol.467
, Issue.7315
, pp. 596-599
-
-
Bollag, G.1
Hirth, P.2
Tsai, J.3
-
28
-
-
13144279271
-
Autoregulation of the Raf-1 serine/threonine kinase
-
Cutler RE Jr, Stephens RM, Saracino MR, Morrison DK. Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci U S A. 1998;95(16):9214–9219.
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, Issue.16
, pp. 9214-9219
-
-
Cutler, R.E.1
Stephens, R.M.2
Saracino, M.R.3
Morrison, D.K.4
-
29
-
-
12144289677
-
Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
-
Wan PT, Garnett MJ, Roe SM, et al; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–867.
-
(2004)
Cell
, vol.116
, Issue.6
, pp. 855-867
-
-
Wan, P.T.1
Garnett, M.J.2
Roe, S.M.3
-
30
-
-
84864258996
-
A landscape of driver mutations in melanoma
-
Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251–263.
-
(2012)
Cell
, vol.150
, Issue.2
, pp. 251-263
-
-
Hodis, E.1
Watson, I.R.2
Kryukov, G.V.3
-
31
-
-
79952379083
-
Targeted therapy in GIST: In silico modeling for prediction of resistance
-
Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol. 2011;8(3):161–170.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, Issue.3
, pp. 161-170
-
-
Pierotti, M.A.1
Tamborini, E.2
Negri, T.3
Pricl, S.4
Pilotti, S.5
-
32
-
-
80051625929
-
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
-
Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085–3096.
-
(2011)
J Clin Oncol
, vol.29
, Issue.22
, pp. 3085-3096
-
-
Wagle, N.1
Emery, C.2
Berger, M.F.3
-
33
-
-
42949149240
-
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
-
Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041–3046.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.8
, pp. 3041-3046
-
-
Tsai, J.1
Lee, J.T.2
Wang, W.3
-
34
-
-
84923917434
-
Molecular insight and resolution for tumors harboring the H-ras (G12V) mutation
-
Tang H-C, Chen Y-C. Molecular insight and resolution for tumors harboring the H-ras (G12V) mutation. RSC Adv. 2015;5(27):20623–20633.
-
(2015)
RSC Adv
, vol.5
, Issue.27
, pp. 20623-20633
-
-
Tang, H.-C.1
Chen, Y.-C.2
-
35
-
-
84939441929
-
Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation
-
Lin TY, Fan CW, Maa MC, Leu TH. Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation. Biomedicine (Taipei). 2015;5(1):5.
-
(2015)
Biomedicine (Taipei)
, vol.5
, Issue.1
, pp. 5
-
-
Lin, T.Y.1
Fan, C.W.2
Maa, M.C.3
Leu, T.H.4
-
36
-
-
85017728067
-
Sambucus williamsii induced embryonic stem cells differentiated into neurons
-
Liu SP, Hsu CY, Fu RH, et al. Sambucus williamsii induced embryonic stem cells differentiated into neurons. Biomedicine (Taipei). 2015; 5(1):3.
-
(2015)
Biomedicine (Taipei)
, vol.5
, Issue.1
, pp. 3
-
-
Liu, S.P.1
Hsu, C.Y.2
Fu, R.H.3
-
37
-
-
84904114051
-
Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine
-
Tang HC, Chen CY. Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine. Biomed Res Int. 2014;2014:798742.
-
(2014)
Biomed Res Int
, vol.2014
, pp. 798742
-
-
Tang, H.C.1
Chen, C.Y.2
-
38
-
-
84939438545
-
The bacterial interactions in the nasopharynx of children receiving adenoidectomy
-
Chen HX, Lai CH, Hsu HY, et al. The bacterial interactions in the nasopharynx of children receiving adenoidectomy. Biomedicine (Taipei). 2015;5(1):6.
-
(2015)
Biomedicine (Taipei)
, vol.5
, Issue.1
, pp. 6
-
-
Chen, H.X.1
Lai, C.H.2
Hsu, H.Y.3
-
39
-
-
79251561193
-
TCM Database@Taiwan: The world’s largest traditional Chinese medicine database for drug screening in silico
-
Chen CY. TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico. PLoS One. 2011;6(1):e15939.
-
(2011)
Plos One
, vol.6
, Issue.1
, pp. e15939
-
-
Chen, C.Y.1
-
40
-
-
84865435981
-
Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization
-
Kong X, Qin J, Li Z, et al. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol Chem. 2012;10(36):7402–7417.
-
(2012)
Org Biomol Chem
, vol.10
, Issue.36
, pp. 7402-7417
-
-
Kong, X.1
Qin, J.2
Li, Z.3
-
41
-
-
80052604878
-
Identification of novel BRAF kinase inhibitors with structure-based virtual screening
-
Park H, Choi H, Hong S. Identification of novel BRAF kinase inhibitors with structure-based virtual screening. Bioorg Med Chem Lett. 2011; 21(19):5753–5756.
-
(2011)
Bioorg Med Chem Lett
, vol.21
, Issue.19
, pp. 5753-5756
-
-
Park, H.1
Choi, H.2
Hong, S.3
-
42
-
-
53549110555
-
Identification of BRAF inhibitors through in silico screening
-
Luo C, Xie P, Marmorstein R. Identification of BRAF inhibitors through in silico screening. J Med Chem. 2008;51(19):6121–6127.
-
(2008)
J Med Chem
, vol.51
, Issue.19
, pp. 6121-6127
-
-
Luo, C.1
Xie, P.2
Marmorstein, R.3
-
43
-
-
33845730781
-
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
-
King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006;66(23):11100–11105.
-
(2006)
Cancer Res
, vol.66
, Issue.23
, pp. 11100-11105
-
-
King, A.J.1
Patrick, D.R.2
Batorsky, R.S.3
-
44
-
-
70349903395
-
Weighted equation and rules–a novel concept for evaluating protein-ligand interaction
-
Chen CY. Weighted equation and rules–a novel concept for evaluating protein-ligand interaction. J Biomol Struct Dyn. 2009;27(3):271–282.
-
(2009)
J Biomol Struct Dyn
, vol.27
, Issue.3
, pp. 271-282
-
-
Chen, C.Y.1
-
45
-
-
67649992844
-
Novel potent BRAF inhibitors: Toward 1 nM compounds through optimization of the central phenyl ring
-
Ménard D, Niculescu-Duvaz I, Dijkstra HP, et al. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. J Med Chem. 2009;52(13):3881–3891.
-
(2009)
J Med Chem
, vol.52
, Issue.13
, pp. 3881-3891
-
-
Ménard, D.1
Niculescu-Duvaz, I.2
Dijkstra, H.P.3
-
46
-
-
84878775187
-
A novel integrated framework and improved methodology of computer-aided drug design
-
Chen CY. A novel integrated framework and improved methodology of computer-aided drug design. Curr Top Med Chem. 2013;13(9):965–988.
-
(2013)
Curr Top Med Chem
, vol.13
, Issue.9
, pp. 965-988
-
-
Chen, C.Y.1
-
47
-
-
84875592758
-
GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit
-
Pronk S, Páll S, Schulz R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29(7):845–854.
-
(2013)
Bioinformatics
, vol.29
, Issue.7
, pp. 845-854
-
-
Pronk, S.1
Páll, S.2
Schulz, R.3
|